ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida. Show more

2200 N. Commerce Parkway, Weston, FL, 33326, United States

Biotechnology

Healthcare

Market Cap

1.498M

52 Wk Range

$0.11 - $1.67

Previous Close

$0.18

Open

$0.20

Volume

4,115

Day Range

$0.18 - $0.20

Enterprise Value

2.395M

Cash

101.8K

Avg Qtr Burn

-413.7K

Insider Ownership

0.02%

Institutional Own.

5.15%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cholesterol Efflux Mediator™ VAR 200 Details Diabetic Kidney Disease	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cholesterol Efflux Mediator™ VAR 200 Details Focal Segmental Glomerulosclerosis And Alport Syndrome	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IC 100 (ASC Inhibitor) Details Cardiometabolic Conditions Associated With Obesity	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.